Light Chain Bioscience (Novimmune)

Develops therapeutic monoclonal antibodies to treat patients suffering from immune-related disorders.

Launch date

Mar 1998

Employees

Market cap

Enterprise valuation

Company register number CH-660.0.428.998-8

Geneva Canton of Geneva (HQ)

Revenues, earnings & profits over time

EUR	2015
Revenues	13.9m

Source: Dealroom estimates

Date	Investors	Amount	Round
-	BZ Bank Bernard Mach Swedish Orphan Biovitrum	N/A	-
May 2000	LODH Immunology Fund Novartis Venture Fund	$14.0m	Series A
Jun 2006	Aravis Ventures LODH Immunology Fund Novartis Venture Fund	$46.0m	Series B
Nov 2006	N/A	N/A	Early VC
May 2009	Aravis Ventures LODH Immunology Fund Varuma Novartis Venture Fund	$54.8m	Series C
Dec 2010	N/A	$22.4m	Series D
Jun 2012	N/A	N/A	Early VC
Oct 2012	N/A	€6.0m	Grant
Feb 2014	Rosetta Capital	$66.0m	Series E
Jan 2016*	Rosetta Capital LODH Immunology Fund Pictet Alternative Advisors Novartis Venture Fund	€27.0m	Series F
Total Funding		€218m

Tech stackLearn more about the technologies and tools that this company uses.

Financials